Viloxazine in the treatmentof depressive neurosis: A controlled clinical study with doxepin and placebo

J. P. McEvoy, W. F. Sheridan, W. R.C. Stewart

Research output: Contribution to journalArticle

5 Scopus citations


In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropranololamine type of β-adreno-receptor antagonists. Initial clinical studies support the hypothesis that viloxazine has antidepressant properties in man.

Original languageEnglish (US)
Pages (from-to)440-443
Number of pages4
JournalBritish Journal of Psychiatry
Issue number5
StatePublished - Jan 1 1980
Externally publishedYes


ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this